The proposed legislation, General Assembly Raised Bill No. 1421, aims to enhance Medicaid coverage for obesity treatment by allowing the Commissioner of Social Services to petition for the approval of generic, lower-cost glucagon-like peptide (GLP-1) prescription drugs from the federal Department of Health and Human Services. Within thirty days of the bill's passage, the commissioner is required to submit this petition and, upon approval, enter into contracts with manufacturers to supply these drugs for HUSKY Health program members. Additionally, the commissioner must develop a strategic plan to maximize access to these medications and minimize costs, with a report due by December 31, 2025.

The bill also establishes an advisory committee tasked with studying ways to improve access to cost-effective prescription drugs for obesity treatment and making recommendations to the Commissioner of Social Services. This committee will consist of patient advocates, pharmacists, and medical professionals, and is required to convene within thirty days of the bill's passage. The committee will review the strategic plan and provide recommendations by January 31, 2026, after which it will terminate. The bill emphasizes the state's commitment to pursuing affordable alternatives to brand-name drugs for Medicaid recipients.